CR:DOI:c8979d6d33702fc9854f30445fad20d0
From IDWiki
{{#scite:
|reference=guery2018ex
|type=journal-article
|title=Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
|author=Benoit Guery;Francesco Menichetti;Veli-Jukka Anttila;Nicholas Adomakoh;Jose Maria Aguado;Karen Bisnauthsing;Areti Georgopali;Simon D Goldenberg;Andreas Karas;Gbenga Kazeem;Chris Longshaw;Jose Alejandro Palacios-Fabrega;Oliver A Cornely;Maria J G T Vehreschild|+sep=;
|journal=The Lancet Infectious Diseases
|publisher=Elsevier BV
|year=2018
|volume=18
|issue=3
|pages=296-307
|doi=10.1016/s1473-3099(17)30751-x
|issn=1473-3099
|retrieved-from=https://dx.doi.org/
|retrieved-on=2026-04-08
}}
